U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C9H13NO3
Molecular Weight 183.2044
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RACEPINEPHRINE

SMILES

CNCC(O)C1=CC(O)=C(O)C=C1

InChI

InChIKey=UCTWMZQNUQWSLP-UHFFFAOYSA-N
InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3

HIDE SMILES / InChI

Molecular Formula C9H13NO3
Molecular Weight 183.2044
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Racepinephrine or racemic epinephrine is a mixture of levo and dextro isomers of epinephrine act as a nonselective agonist at adrenergic receptors. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, shortness of breath. Inhaled racepinephrine became available in September 2012 as a nonprescription treatment for bronchospasm based on a 1986 US Food and Drug Administration rule. Besides, racemic epinephrine relieves respiratory distress in hospitalized infants with bronchiolitis and is safe but does not abbreviate hospital stay. Morbidity associated with bronchiolitis as identified by parents persists for at least one week after hospital discharge in most infants.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

For temporary relief of mild symptoms of intermittent asthma: wheezing, tightness of chest, shortness of breath
Palliative
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
unknown, 2 years
n = 1
Health Status: unknown
Age Group: 2 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hypertension, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Hypertension (5.4%)
Tachycardia (5.4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypertension 5.4%
Disc. AE
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
unknown, 2 years
n = 1
Health Status: unknown
Age Group: 2 years
Sex: M
Population Size: 1
Sources:
Tachycardia 5.4%
Disc. AE
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
unknown, 2 years
n = 1
Health Status: unknown
Age Group: 2 years
Sex: M
Population Size: 1
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding.
1998 Apr 1
[Endoscopic mucosal resection of premalignant lesions of the upper gastrointestinal tract].
2001 Nov
Cytotoxic effects of gingival retraction cords on human gingival fibroblasts in vitro.
2004 Apr
Cardiovascular responses of Chinook salmon (Oncorhynchus tshawytscha) during rapid anaesthetic induction and recovery.
2004 Feb
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
2004 Feb
MAPK-dependent regulation of IL-1- and beta-adrenoreceptor-induced inflammatory cytokine production from mast cells: implications for the stress response.
2004 Sep 21
[Experimental studies of rhizoma Astilbes chinensis on its effects in abirritation, blood activation, cough relieving and sputum elimination].
2006 Dec
Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958-1978.
2006 Jan
Stereospecificity of mushroom tyrosinase immobilized on a chiral and a nonchiral support.
2007 May 30
Electrical nerve stimulation or ultrasound guidance for lateral sagittal infraclavicular blocks: a randomized, controlled, observer-blinded, comparative study.
2008 Jun
Analysis of efficacy of chiral adrenergic agonists.
2008 Mar
Caffeine and anaerobic performance: ergogenic value and mechanisms of action.
2009
Simultaneous determination of epinephrine, uric acid and xanthine in the presence of ascorbic acid using an ultrathin polymer film of 5-amino-1,3,4-thiadiazole-2-thiol modified electrode.
2009 Aug 4
The impact of platelet function or C-reactive protein, on cardiovascular events after an acute myocardial infarction.
2009 Jul 7
High concentrations of dexmedetomidine inhibit compound action potentials in frog sciatic nerves without alpha(2) adrenoceptor activation.
2010 Aug
Patents

Sample Use Guides

Bronchiolitis: 0,1ml<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml >10kg of racemic adrenaline (racepinephrine) 20mg/ml diluted in 2ml NaCl. Maximum 12 inhalations/24 hours
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:01:50 UTC 2023
Edited
by admin
on Sat Dec 16 17:01:50 UTC 2023
Record UNII
GR0L9S3J0F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RACEPINEPHRINE
USP  
Common Name English
2-(METHYLAMINO)-1-(3,4-DIHYDROXYPHENYL)ETHANOL
Systematic Name English
RACEPINEPHRINE [USP MONOGRAPH]
Common Name English
DL-ADRENALINE
Common Name English
EPINEPHRINE, DL-
Common Name English
BENZYL ALCOHOL, 3,4-DIHYDROXY-.ALPHA.-((METHYLAMINO)METHYL)-, (±)-
Systematic Name English
EPIRENAMINE
Common Name English
EPINEPHRINE DL-FORM
MI  
Common Name English
1,2-BENZENEDIOL, 4-(1-HYDROXY-2-(METHYLAMINO)ETHYL)-
Systematic Name English
racepinefrine [INN]
Common Name English
EPINEPHRINE DL-FORM [MI]
Common Name English
EPINEPHRINE RACEMIC
Common Name English
1-(3,4-DIHYDROXY)PHENYL-2-METHYLAMINOETHANOL
Common Name English
RACEPINEFRINE
INN   WHO-DD  
INN  
Official Name English
Racepinefrine [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C48149
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
Code System Code Type Description
RXCUI
66887
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID80858965
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
INN
4553
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
CAS
8059-19-6
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
SUPERSEDED
ChEMBL
CHEMBL1740
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
SMS_ID
100000085694
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
DAILYMED
GR0L9S3J0F
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
EVMPD
SUB10238MIG
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
DRUG CENTRAL
4508
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
ECHA (EC/EINECS)
206-347-6
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
NCI_THESAURUS
C76546
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
DRUG BANK
DB11124
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
CHEBI
33568
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
CAS
329-65-7
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
MERCK INDEX
m4944
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY Merck Index
CAS
6912-68-1
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
SUPERSEDED
CAS
8060-13-7
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
SUPERSEDED
PUBCHEM
838
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
FDA UNII
GR0L9S3J0F
Created by admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
ENANTIOMER -> RACEMATE
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY